CoChat
Sign Up
Cited by 678Allergic Rhinitis and SensitizationFood Allergy and Anaphylaxis ResearchAsthma and respiratory diseases

The DOI matches its Crossref record; 312 of the 321 references it cites were found in a registry or an index.

Allergen injection immunotherapy for seasonal allergic rhinitis

Open access
Calderon, Moises A, Alves, Bernadette, Jacobson, Mikila, Hurwitz, Brian, Sheikh, Aziz, Durham, Stephen·2007·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd001936.pub2PMC PMC7017974
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Allergic rhinitis is the most common of the allergic diseases. Despite improved understanding of the pathophysiology of allergic rhinitis and advances in its pharmacological treatment, its prevalence has increased worldwide. For patients whose symptoms remain uncontrolled despite medical treatment, allergen injection immunotherapy is advised. An allergen-based treatment may reduce symptoms, the need for medication and modify the natural course of this disease. OBJECTIVES: To evaluate the efficacy and safety of subcutaneous specific allergen immunotherapy, compared with placebo, for reducing symptoms and medication requirements in seasonal allergic rhinitis patients. SEARCH STRATEGY: We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 1 2006), MEDLINE (1950 to 2006), EMBASE (1974 to 2006), Pre-MEDLINE, KOREAMED, INDMED, LILACS, PAKMEDINET, Scisearch, mRCT and the National Research Register. The date of the last search was February 2006. SELECTION CRITERIA: All studies identified by the searches were assessed to identify randomised controlled trials involving participants with symptoms of seasonal allergic rhinitis and proven allergen sensitivity, treated with subcutaneous allergen specific immunotherapy or corresponding placebo. DATA COLLECTION AND ANALYSIS: Two independent authors identified all studies reporting double-blind, placebo controlled randomised trials of specific immunotherapy in patients with seasonal allergic rhinitis due to tree, grass or weed pollens. Two authors independently performed quality assessment of studies. Data from identified studies were abstracted onto a standard extraction sheet and subsequently entered into RevMan 4.2.8. Analysis was performed using the Standardised Mean Difference (SMD) method and a random-effects model; P values < 0.05 were considered statistically significant. The primary outcome measures were symptom scores, medication use, quality of life and adverse events. MAIN RESULTS: We retrieved 1111 publications of which 51 satisfied our inclusion criteria. In total there were 2871 participants (1645 active, 1226 placebo), each receiving on average 18 injections. Duration of immunotherapy varied from three days to three years. Symptom score data from 15 trials were suitable for meta-analysis and showed an overall reduction in the immunotherapy group (SMD -0.73 (95% CI -0.97 to -0.50, P < 0.00001)). Medication score data from 13 trials showed an overall reduction in the immunotherapy group (SMD of -0.57 (95% CI -0.82 to -0.33, p<0.00001)). Clinical interpretation of the effect size is difficult. Adrenaline was given in 0.13% (19 of 14085 injections) of those on active treatment and in 0.01% (1 of 8278 injections) of the placebo group for treatment of adverse events. There were no fatalities. AUTHORS' CONCLUSIONS: This review has shown that specific allergen injection immunotherapy in suitably selected patients with seasonal allergic rhinitis results in a significant reduction in symptom scores and medication use. Injection immunotherapy has a known and relatively low risk of severe adverse events. We found no long-term consequences from adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001936.pub2

Cites

312 of 312 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 29

  1. Brewczynski, 1999, Efficacy and safety of immunotherapy with modified grass pollen allergens. Results of a placebo-controlled study, Allergologie, 22, 411
  2. Hauser, 1995, Inhibitory effect on migration of inflammatory cells into the nasal mucosa by immunotherapy, Allergo Journal, 4, 164
  3. Berstein, 2001, Double blind placebo controlled (DBPC) study of grapeseed extract in the treatment of seasonal allergic rhinitis (SAR), Journal of Allergy and Clinical Immunology, 107, S311
  4. Calderon, 2003, Double blind placebo controlled study of specific immunotherapy (SIT) with Alutard SQ grass pollen for seasonal allergic rhinoconjunctivitis, Allergy and Clinical Immunology International, 1, Abstract No. O-
  5. Crimi, 2001, A randomised double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic-rhinitis: effects on clinical and inflammatory markers, European Respiratory Journal, 18, 482s
  6. Egger, 1997, The influence of hypo-sensitisation therapy on the sense of smell in subjects with seasonal allergic rhinitis, Allergologie, 20, 525
  7. Frankland, 1963, Treatment of hay fever by depot injection (shypyrindene) in allergic conditions. Double blind clinical study, Acta Allergologica, 18, 175
  8. Kerr, 1964, The treatment of hay fever including a controlled trial of the use of alum precipitate pollen adsorbate, Acta Allergologica, 19, 76
  9. Kuhn, 1985, Hyposensitization in pollen sensitive children: A 3 year prospective study, Allergologie, 8, 103
  10. Lindsay-Miller, 1971, Pollen Tyrosine in the treatment of hay fever, Clinical Allergy, 1, 351
  11. Malling, 2000, Allergen specific immunotherapy for asthma, Ugeskr Laeger, 162 (4), 477
  12. Manger, 1984, Hyposensitization of hay fever patients with Tyrosin-adsorbed grass and rye pollen allergoid. Clinical and immunological parameters during different dosages with TA Tyrosin-Allergoid Gräserpollen, Allergologie, 7, 222
  13. Mewes, 1999, Short term immune therapy with ALK7 reduces grass-pollen induces rhinoconjunctivitis symptoms and the specific nasal reactivity is more efficient than a symptomatic standard therapy, Allergologie, 22, 581
  14. Nolte, 1999, Allergen extracts, dosing, efficacy and safety of immunotherapy, International Review of Allergology and Clinical Immunology, 5 (3), 184
  15. Osterballe, 1982, Immunotherapy in hay fever with timothy major allergens, Allergy, 37, 8
  16. Pastorello, 1988, A double blind placebo controlled trial of specific immunotherapy with aluminium hydroxide adsorbed allergoid in grass pollen induced rhinitis, Allergy, 43, 48
  17. Ricca, 1997, Preseasonal specific immunotherapy with modified Phleum pratense allergenic extracts: tolerability and effects, Allergologia et Immunopathologia (Madrid), 25, 167
  18. Rozniecka, 1995, The characteristics of pollinosis during the pollen season and the influence of specific immunotherapy. Part II: Cytologic changes and chemotactic activity in nasal lavage, Pneumonologia i Alergologia Polska, 63, 144
  19. Ruiz, 2001, Safety and efficacy of immunotherapy with a standardized depigmented and glutaraldehyde-polyerized extract of phleum pratense pollen, Journal of Allergy and Clinical Immunology, 107, S260
  20. Sandstrom, 2001, Xolair is effective in the treatment of seasonal birch pollen allergic rhinitis, Annals of Allergy, Asthma and Immunology, 86, 83
  21. Stuck, 2001, Birch pollen allergoid plus MPL in short-term immunotherapy, Otolaryngology - Head and Neck Surgery, 125, P199
  22. Sykora, 2004, Efficacy and safety of specific allergen immunotherapy with standardized depod allergen H-AI depot (pollens), Alergie, 6, 170
  23. Watanabe, 2003, Successful grass pollen immunotherapy inhibits eosinophil accumulation in the nasal mucosa: role of adhesion molecules and apoptosis [Abstract], Allergy and Clinical Immunology International, 15, Abstract No.O-1
  24. Williams, 2001, A study to determine the efficacy of a nasally administered rye grass peptide, Ptl-0901, in the treatment of severe seasonal hayfever, Journal of Allergy and Clinical Immunology, 107, S256
  25. Williams, 2002, Effectiveness of preseasonal allergoid immunotherapy in patients with grass pollen allergy [Abstract], Allergy, 57, 51
  26. Yariktas, 2002, Comparison of Leukotriene Receptor Antagonist and Antihistamine Therapy in Seasonal Allergic Rhinitis, Turkish Archives of Otolaryngology, 40, 252
  27. Frank, 2001, Effectiveness of a pre-seasonal allergoid immunotherapy in patients with seasonal allergic rhinitis due to grass pollen, Journal of Allergy and Clinical Immunology, 107, S260
  28. Committee of the Safety of Medicine, 1994, Desensitising vaccines: New advice, Current Problems in Pharmacovigilance, 20, 5
  29. Durham, 1999, Long-term clinical efficacy of grass-pollen immunotherapy, New England Journal of Medicine, 341(7), 468, 10.1056/NEJM199908123410702 · DOI

Cited by

Sorted by citations

See all 678

Related

See all

Metadata

Authors
Calderon, M. A., Alves, B., Jacobson, M., Hurwitz, B., Sheikh, A., & Durham, S.
Affiliations
  • Royal Brompton Hospital; Department of Allergy and Respiratory Medicine; Imperial College School of Medicine at the National Heart and Lung Institute London UK SW3 6LY
  • Brighton and Hove City Council (GB)
  • Imperial College London (GB)
  • King's College London (GB)
  • University of Edinburgh (GB)
  • Royal Brompton Hospital (GB)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2007-01-24
Volume
2009
Issue
1
Pages
CD001936-CD001936
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd001936.pub2
PMC
PMC7017974
OpenAlex
W2153011983
Cited by
678
References
321
Citations by year
2026: 4 · 2025: 6 · 2024: 17 · 2023: 20 · 2022: 31 · 2021: 14 · 2020: 19 · 2019: 24 · 2018: 34 · 2017: 38 · 2016: 41 · 2015: 53 · 2014: 51 · 2013: 50 · 2012: 53
FWCI
4.24
Type
journal article
Language
en
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
allergen immunotherapy, allergic rhinitis, tree pollen, grass pollen, weed pollen, symptom scores, medication use, quality of life, adverse events, placebo comparison, treatment efficacy and safety, treatment duration, allergen sensitivity, allergen avoidance, allergen desensitization, allergen tolerance
MeSH terms
Allergens, Desensitization, Immunologic, Rhinitis, Allergic, Seasonal, Humans, Injections, Subcutaneous, Pollen, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review